BioNTech and Pfizer have secured approval from the German regulatory authority, Paul-Ehrlich-Institut, to conduct a Phase I/II clinical trial of a Covid-19 vaccine candidate.
The candidate, BioNTech’s BNT162, is intended to prevent Covid-19 infection. BioNTech and Pfizer are co-develping the vaccine programme.
Said to be the first Covid-19 vaccine trial to launch in Germany, the study is part of a global development programme.
Related
Related Companies
Content from our partners
